Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Kaiser

Showing results (101-110 of 160) with videos related to

Pageof 16
Sort By:
The Lancet. Haematology|April 22, 2021
Response to first vaccination against SARS-CoV-2 in patients with multiple myelomaSarah Bird, Aikaterini Panopoulou, Robyn L Shea, et al.
British Journal of Cancer|July 21, 2017
Active multiple myeloma suppresses and typically eliminates coexisting MGUSJohn P Campbell, Jennifer L J Heaney, Sankalp Pandya, et al.
British Journal of Haematology|June 16, 2026
Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trialAndrew Hall, James Croft, Katrina Walker, et al.
Blood|November 11, 2006
Circulating proteasome levels are an independent prognostic factor for survival in multiple myelomaChristian Jakob, Karl Egerer, Peter Liebisch, et al.
Leukemia & Lymphoma|June 11, 2014
A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescuePing Wu, Brian A Walker, Annemiek Broyl, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 8, 2021
Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple MyelomaJessica Caro, David Cairns, Tom Menzies, et al.
British Journal of Haematology|May 31, 2013
Improved risk stratification in myeloma using a microRNA-based classifierPing Wu, Luca Agnelli, Brian A Walker, et al.
Leukemia|June 22, 2018
Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trialsJennifer L J Heaney, John P Campbell, Gulnaz Iqbal, et al.
BMJ Open|October 5, 2022
Development of machine learning support for reading whole body diffusion-weighted MRI (WB-MRI) in myeloma for the detection and quantification of the extent of disease before and after treatment (MALIMAR): protocol for a cross-sectional diagnostic test accuracy studyLaura Satchwell, Linda Wedlake, Emily Greenlay, et al.
Blood Advances|July 5, 2022
Clinical characteristics and outcomes of IgD myeloma: experience across UK national trialsCharles Agbuduwe, Gulnaz Iqbal, David Cairns, et al.
Pageof 16

Showing results (101-110 of 160) with videos related to

Sort By:
Pageof 16
The Lancet. Haematology|April 22, 2021
Response to first vaccination against SARS-CoV-2 in patients with multiple myelomaSarah Bird, Aikaterini Panopoulou, Robyn L Shea, et al.
British Journal of Cancer|July 21, 2017
Active multiple myeloma suppresses and typically eliminates coexisting MGUSJohn P Campbell, Jennifer L J Heaney, Sankalp Pandya, et al.
British Journal of Haematology|June 16, 2026
Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trialAndrew Hall, James Croft, Katrina Walker, et al.
Blood|November 11, 2006
Circulating proteasome levels are an independent prognostic factor for survival in multiple myelomaChristian Jakob, Karl Egerer, Peter Liebisch, et al.
Leukemia & Lymphoma|June 11, 2014
A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescuePing Wu, Brian A Walker, Annemiek Broyl, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 8, 2021
Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple MyelomaJessica Caro, David Cairns, Tom Menzies, et al.
British Journal of Haematology|May 31, 2013
Improved risk stratification in myeloma using a microRNA-based classifierPing Wu, Luca Agnelli, Brian A Walker, et al.
Leukemia|June 22, 2018
Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trialsJennifer L J Heaney, John P Campbell, Gulnaz Iqbal, et al.
BMJ Open|October 5, 2022
Development of machine learning support for reading whole body diffusion-weighted MRI (WB-MRI) in myeloma for the detection and quantification of the extent of disease before and after treatment (MALIMAR): protocol for a cross-sectional diagnostic test accuracy studyLaura Satchwell, Linda Wedlake, Emily Greenlay, et al.
Blood Advances|July 5, 2022
Clinical characteristics and outcomes of IgD myeloma: experience across UK national trialsCharles Agbuduwe, Gulnaz Iqbal, David Cairns, et al.
Pageof 16